



# Financial Tear Sheet

## Corporate Profile

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

## Primary IR Contact

Jennifer Robinson

**Phone:** 617-674-9873

**E-mail:**

[jrobinson@rapharma.com](mailto:jrobinson@rapharma.com)

## Stock Performance

### RARX (Common Stock)

**Exchange** NASDAQ (US Dollar)

**Price** **\$15.27**

**Change (%)** ▲  
**0.11 (0.73%)**

**Volume** 179,699

**52 Week Low** \$12.05

**Market Cap** \$342,762,233

**Rolling EPS** -2.20

**PE Ratio** 0



**Shares Outstanding** 22,609,646

Data as of August 17, 2017 4:00 p.m. ET

## Recent Headlines & Events

August 9, 2017 - 4:18 p.m.

[Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)

There are currently no events scheduled.

July 31, 2017 - 7:12 a.m.


[Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria](#)

July 19, 2017 - 4:06 p.m.

[Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis](#)

## Analyst Estimates / Ratings

Mean Recommendation: **1.8**



### EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	-0.60	-0.54	-0.55
QTR	Dec 17	-0.64	-0.57	-0.58
QTR				
QTR				
FY	Dec 17	-2.24	-2.12	-2.17
FY	Dec 18	-2.09	-2.03	-2.21

## SEC Filings

Filing Date	Form
08/10/17	SC 13G/A
08/09/17	10-Q
06/26/17	8-K
06/22/17	4

## Corporate Governance

**Robert Heft**  
Director

**Jason Lettmann**  
Director

**Ed Mathers**  
Director

**Tim Pearson**  
Director

**Rajeev Shah**  
Director

**Peter Tuxen-Bisgaard**  
Director

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	110	396.73	102.4	23,155,407
Mutual Fund	119	33.09	8.2	1,862,170
Insider *	2	26.11	9.9	2,235,854

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
New Enterprise Associates (NEA)	3,493,636	15.5	0	June 30, 2017
Morgenthaler Ventures	2,745,846	12.1	2,745,846	October 25, 2016
Wellington Management Company, LLP	2,300,439	10.2	195,375	July 31, 2017
Novartis AG	2,252,157	10.0	-208,880	June 19, 2017
Novo Holdings A/S	2,031,562	9.0	0	June 30, 2017
RA Capital Management, LLC	1,351,808	6.0	0	June 30, 2017
Plain (Plain)	1,320,657	5.8	1,320,657	October 25, 2016
Lightstone Ventures, L.P.	1,320,655	5.8	1,320,655	December 31, 2016
VHCP Management, LLC	769,771	3.4	44,742	June 30, 2017
Rock Springs Capital Management LP	600,000	2.7	-188,959	June 30, 2017

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)